Cyplasin Biomedical Ltd., announces the formation of a wholly owned subsidiary to be called Syngar Technologies Inc. and entering into an option license agreement for a technology called PLUS Wave



    CPBM: OTCBB

    EDMONTON, Aug. 11 /CNW/ - Cyplasin Biomedical Ltd., announced today that
it has created a new subsidiary company called Syngar Technologies Inc. The
creation of this wholly owned subsidiary is in part to signal that the company
is going in a new direction and that eventually the parent company will adopt
the name of Syngar Technologies Inc., once certain filings and registrations
are completed.
    Further Cyplasin has entered into a license agreement for the enhanced
production of biofuels from sugar, starch, cellulose and algae biomass
sources. The proprietary technology will be called Pulsed Low Ultra Sound Wave
technology (PLUS Wave). Conditional upon certain corporate and financing goals
being met the license is to be fully sublicensable on an exclusive world wide
basis. The licensing terms include up front licensing fees and a yearly
maintenance fee.
    "We have chosen to expand our technical focus and develop PLUS Wave(TM)
because we see this as an opportunity to bring new technology and revenue into
the company while delivering on increased shareholder value," stated Mr. Garth
Likes President and CEO of Cyplasin. He went on to say, "the PLUS Wave
technology can also be applied to various biomedical and industrial
applications and we are hopeful that once the biofuels project is under way we
can also initiate projects in these other areas as well". The biofuels market
is expected to grow rapidly and is estimated to be currently worth US$ 24
billion.
    "As part of our expanded focus we are in the process of designing a new
website www.syngar.com and this should be available in the ensuing weeks. The
old website address www.cyplasin.com is no longer valid for the company and
has been taken down" stated Mr. Likes.

    About PLUS Wave Technology

    PLUS Wave (Pulsed Low Ultra Sound Wave) technology is able to stimulate
cells in any bioreactor or fermentation tank via a proprietary process that
uses low ultrasound wave frequencies. Cells normally contained in bioreactors
are able to break down cellulose materials such as grass into components which
include various sugars. These sugars in turn can then be fermented to become
ethanol which can then be blended with gasoline for use in any gasoline
engine. PLUS Wave is able to increase this process from 30-50% depending upon
the fermentation system used, thus making the use of cellulose derived
biofuels very economical. "We now need to further develop the PLUS Wave
technology for commercial scale use and if the efficiencies continue to bear
out PLUS Wave will become a major disruptive technology in multiple areas"
states Mr. Likes.

    About Syngar Technologies Inc.

    Syngar Industries will have a focus on the development of clean tech and
alternative energy technologies.

    Forward Looking Statements

    This news release contains "forward-looking statements", as that term is
defined in Section 27A of the United States Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this current report
which are not purely historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions regarding the
future.
    Actual results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others, the
inherent uncertainty of financial estimates and projections, the competitive
and regulatory environments, stock market conditions, unforeseen technical
difficulties and our ongoing ability to operate a business and obtain
financing. These forward-looking statements are made as of the date of this
news release, and we assume no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from
those projected in the forward-looking statements.
    Although we believe that our beliefs, plans, expectations and intentions
contained in this current report are reasonable, there can be no assurance
that such beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in our quarterly
reports on Form 10-Q and our other periodic reports filed from time-to-time
with the Securities and Exchange Commission pursuant to the Securities
Exchange Act.





For further information:

For further information: and inquiries contact Garth Likes,
President/CEO, Unit 131, Advanced Technology Centre, 9650-20th Ave, Edmonton,
Alberta, (780) 990-4539, glikes@syngar.com

Organization Profile

CYPLASIN BIOMEDICAL LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890